



BIO DATA

Prof. Neerati Prasad, M.Pharm., Ph.D., PDF (USA).

Professor in Pharmacy
Department of Pharmacology
University College of Pharmaceutical Sciences
Kakatiya University, Hanumakonda, 506009
TELANGANA, India.

Mobile No: 09494812120

prasadneerati@gmail.com

prasadneerati@kakatiya.ac.in



ACADEMIC QUALIFICATIONS

Examination / Degree	Name of the Board/University	year of award of the degree	Division	% of Marks
SSC	Board of Secondary Education	1991	I	74.16%
Intermediate	Board of Technical Education	1994	I	89.53%
Under Graduate	Kakatiya University, Warangal	1999	I	65.80%
Post-Graduate	Kakatiya University, Warangal	2002	I	75.50%
Other Examinations, if any(Pre-PhD)	Kakatiya University, Warangal	2007	Distinction University Topper II I	70.1%

RESEARCH DEGREE(S)

Degree	Title	Date and Year of Award	University
M.Pharm.	Bacteramia amongst the Leprosy Patients	June, 2002	Kakatiya University, Warangal
Ph.D./D.Phil.	Isolation and Characterization of probable potential pharmacological agents from animals and their waste	12-12-2007	Kakatiya University, Warangal
PDF	Tumor Glycomics Research with Emphasis in Biomarker Discovery and Characterization of Tumor Targeting Agents: Regulation of Metastasis by Endogenous Angioinhibitors	2015	SRI International, California, USA



PERIOD OF TEACHING AND RESEARCH EXPERIENCE IN YEARS

P.G. Classes	: 16 years
U.G. Classes	: 18 years
Research (Excluding years spent in M.Phil./Ph.D.)	: 15 years

RESEARCH INTERESTS:

1. Clinical Pharmacokinetics
2. Pharmacokinetics and Drug metabolism
3. Drug Transport
4. Cancer metastasis-role of phyto-polyphenols
5. Toxicological studies
6. Pharmacological screening of new chemical entities from natural sources

FELLOWSHIPS:

1. C.V. Raman Fellow-UGC
2. UGC Research fellowship for PhD

PROFESSIONAL MEMBERSHIPS:

1. Life Member of Association of Pharmaceutical teachers of India (APTI).
2. Life Member of Indian Pharmacological Society (IPS)
3. Life Member of Indian Pharmacy Graduates Association (IPGA)
4. Life Member of Society of Toxicology, India (STOX).

ACADEMIC POSITIONS HELD

1. Joint Director for Pharmacy Hostel, K.U for 6 years
2. Director for Pharmacy Hostel, K.U for 1.5 years
3. Chairman- Board of Studies of K.U for 2 years
5. Member- Board of Studies of K.U and Palamuru University.

FIELDS OF SPECIALIZATION UNDER THE SUBJECT / DISCIPLINE

1. Human Anatomy and physiology, Pharmacology, Hospital Pharmacy.
2. Clinical Pharmacology&Toxicology, Preclinical Evaluation & screening Methods.
3. Pharmaceutical Sciences



M.PHARM PROJECTS GUIDED : 64

PhD DEGREES AWARDED : 05

SEMINARS / CONFERENCES ATTENDED (National and international)

Paper Presentations in Conferences:

1. **Prasad N***, Amuda P and Prabhakar MC 2001. "Correlation between the presence of *M.leprae* in nostrils and blood of LL patients". Paper presented in Indian Association of Leprologists in Patna 2001.
2. **Prasad N*** and Prabhakar MC 2006. "Study of the Morphological Index among the leprosy patients relieved from the treatment(RFT)". Paper presented in IPC,Hyderabad.
3. **Prasad N***, Uday V, Praveen B, Murali G, Ramakrishna D, Prabhakar MC 2008. " Invitro cardiotoxic activity of some animal bile secretions". IJP ,41st Annual Conference of Indian Pharmacological Society & International Conference on Translational Pharmacology 2008;Volume :40,October 2008,Supplement 2: S97, (214).
4. **Prasad N***, Uday V, Praveen B, Murali G, Ramakrishna D, Prabhakar MC 2008. "Effects of some animal bile secretions on the normal heart". IJP ,41st Annual Conference of Indian Pharmacological Society & International Conference on Translational Pharmacology 2008;Volume :40,October 2008,Supplement 2: S108, (252).
5. **Dinesh.G**, Satish Kumar.B,Praveen Kumar.B and **Prasad.N.*** Effect of verapamil on intestinal permeability of phenetoin by insitu perfusion technique in rats. IJP , Annual Conference of Indian Pharmacological Society & International Conference on Translational Pharmacology 2010;Volume :42,December 2010,Supplement 2: Page No.274-275.
6. Satish Kumar Bedada and **Prasad Neerati**. Resveratrol pretreatment affects CYP 3A4 activity in health human volunteers.Spira Awards-2014,Spira Labs Hyderabad.
7. Satish Kumar Bedada , Mahathi Tumparla and **Prasad Neerati**. Study on influence of diosmin pretreatment on metabolism and disposition of carbamazepine. 46th annual conference IPS, 2013, Bangalore.
8. Satish Kumar Bedada , Arun Kumar Parakala and **Prasad Neerati**. Pharmacokinetic interactions between piperine and fexofenadine in human volunteers. 46th annual conference IPS, 2013, Bangalore.
9. Satish Kumar Bedada , Manoj Kumar Chepuri and **Prasad Neerati**. Resveratrol pretreatment affects CYP2E1 in healthy human volunteers. 46th annual conference IPS, 2013, Bangalore.
10. Satish Kumar Bedada and **Prasad Neerati**. Effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine in rats. RAPS-2012,UCPSc KU warangal.
11. Suresh Palle and **Prasad Neerati**. Quercetin nanoparticles attenuates scopolamine induced spatial memory deficits and pathological damages in rats. 68th Indian Pharmaceutical Congress, Vishakapatnam,Dec,2016.

Invited international podium presentations:

1. 3rd World Congress on Diabetes & Metabolism. Title: Influence of curcumin on pioglitazone metabolism and pk/pd: Diabetes mellitus. *Neerati Prasad*, Kakatiya University, India September 24-26, (2012)_ Marriott Hotel & Convention Centre, Hyderabad, India
2. World Congress on Biotechnology. (as speaker), conducted by Bright Technologies,India on 4-6 May,2012. **(Recieved Best Poster Evaluation Award)**
3. International conference on "Recent advances in Drug discovery" (as Session Chair), A.P, India. October 22-24,2010.



4. **49th** Annual conference of Indian Pharmacological Society as a **PARTICIPANT** at Post Graduate Institute of Medical Sciences, Chandigarh on 20-23-October 2016.
5. **49th** Annual conference of Indian Pharmacological Society participated in **Oral PRESENTATION** at Post Graduate Institute of Medical Sciences, Chandigarh on 20-23-October 2016.

INVITED LECTURES IN INTERNATIONAL CONFERENCE(S)

1. Biomarkers-2011. 2nd World Congress on Biomarkers & Clinical Research (as a speaker), Baltimore, USA. September, 12-14, 2011.
2. International conference: INTERVENTIONAL HEPATOLOGY - Updates on interventional procedures under sonographic guidance in Hepatobiliary diseases (as a speaker), RAVELLO - AMALFI COAST (SA), ITALY. May 26 - 28, 2011.
3. During The International Conference **NanoSciTech 2017** held at Punjab University, Chandigarh, India during November 09-10, 2017 delivered Invited Lecture on "Role of nanophytoestrogens in the treatment of neurodegenerative disorders".

ACADEMIC STAFF COLLEGE ORIENTATION/REFRESHER COURSES ATTENDED

Induction Training Programme for faculty in Universities/College/Institutes of Higher education sponsored by PMMMNMTT, MHRD, Govt of India at NIT-Warangal for **Four Weeks from 27, Nov to 24, Dec, 2017.**

LIST OF RESEARCH PUBLICATIONS

1. Sangeeth Kumar Munigadapa, Neerati P: **New steroidal derivative from the skin of Indian Toad (*Bufo melanostictus*) as hypolipidemic and CYP3A inhibitor (Accepted).** *Tropical Journal of Pharmaceutical Research* 2021(Accepted) (Impact Factor: 0.533). <http://dx.doi.org/10.4314/tjpr.v21i1.X>.
2. Lyagala K, Neerati P: **Atorvastatin enhanced the bioavailability of irinotecan by inhibition of permeability-glycoprotein in rats with colon cancer: In vivo and in vitro studies.** *Journal of Natural Science, Biology and Medicine* 2021, **12:57.** (Impact Factor: 0.672).
3. Prasad Neerati, BLA: **Improved bioavailability of linagliptin by resveratrol in rats-involvement of permeability glycoprotein (P-gp) inhibition.** *International journal of pharmaceutical sciences and research* 2021, **12:2237-2246.**
4. Neerati P: **Novel Indole derivative as first P-glycoprotein inhibitor from the skin of Indian toad (*Bufo melanostictus*).** *Turkish Journal of Pharmaceutical Sciences* 2021(In Press), **In Press:In Press.** (Impact Factor: 0.950). DOI: 10.4274/tjps.galenos.2021.47417.
5. Neerati P, Enumula V: **Gallic Acid Improved Amytryptiline Effect in Neuropathic Pain Induced by Partial Sciatic Nerve Ligation (PSNL) in Rats.** *The Natural Products Journal* 2021, **11:663-672.** (Impact Factor: 1.01).
6. Neerati P, Prathapagiri H: **Alpha lipoic acid attenuated neuropathic pain induced by chronic constriction Injury of sciatic nerve in rats.** *Clinical Phytoscience* 2021, **7:1-10.**



7. Athukuri BL, Neerati P: **Enhanced oral bioavailability of diltiazem by resveratrol in healthy human subjects: An open-label, two-period, sequential study.** *Journal of Natural Science, Biology and Medicine* 2020, **11**:100. (Impact Factor: 0.672).
8. Danaboina KK, Neerati P: **Evidence-based P-glycoprotein inhibition by green tea extract enhanced the oral bioavailability of atorvastatin: from animal and human experimental studies.** *Journal of Natural Science, Biology and Medicine* 2020, **11**:105. (Impact Factor: 0.672).
9. Madugula NK, Neerati P: **Influence of Toad Parotid Gland Secretion from Indian Toad (*Bufo melanostictus*) in Diabetic Rats: An Experimental Evidence of P-Glycoprotein Inhibition.** *Journal of Pharmaceutical Research International* 2020:125-135. (Impact Factor: 0.67).
10. Mohana J PN: **Neuroprotective Effect of Alpha Lipoic Acid on Rotenone Induced Neurodegeneration In Zebra Fish.** *International Journal of Biology, Pharmacy and Allied Sciences* 2020, **9**:3333-3349. (Impact Factor: 1.709).
11. Prasad N KMa: **Toxinous Secretions From Indian Toad (*Bufo Meanostictus*) with Potential Antioxidant and Anti-Inflammatory Activities.** *International Journal of Biology, Pharmacy and Allied Sciences* 2020, **9**:3283-3301. (Impact Factor: 0.672).
12. Sriramoju B, Neerati P, Kanwar RK, Kanwar JR: **Corrigendum to" Brain targeted PLGA nanocarriers alleviating amyloid-B expression and preserving basal survivin in degenerating mice model"[*Biochim. et Biophys. Acta (BBA)-Mol. Basis Dis.* 1852 (11)(November 2015) 2423-2431].** *Biochimica et biophysica acta Molecular basis of disease* 2020, **1866**:165902. (Impact Factor: 5.187).
13. Neerati P, Palle S: **Resveratrol nanoparticle pretreatment improved the oral bioavailability of bromocriptine: Involvement of liver and intestinal CYP3A enzyme inhibition.** *Journal of Natural Science, Biology and Medicine* 2019, **10**:209. (Impact Factor: 0.672).
14. Bedada SK, Neerati P: **Modulation of CYP3A enzyme activity by diosmin and its consequence on carbamazepine pharmacokinetics in rats.** *Naunyn-Schmiedeberg's Archives of Pharmacology* 2018, **391**:115-121. (Impact Factor:3.03)
15. Bedada SK, Neerati P: **Evaluation of the effect of quercetin treatment on CYP2C9 enzyme activity of diclofenac in healthy human volunteers.** *Phytother Res* 2018, **32**:305-311. (Impact Factor:5.83)
16. Bedada SK, Neerati P: **The effect of quercetin on the pharmacokinetics of chlorzoxazone, a CYP2E1 substrate, in healthy subjects.** *Eur J Clin Pharmacol* 2018, **74**:91-97. (Impact Factor:2.96)
17. Bedada SK, Neerati P: **Response: Similar effect of quercetin on CYP2E1 and CYP2C9 activities in humans?** *Eur J Clin Pharmacol* 2018, **74**:1189-1190. (Impact Factor:2.96)
18. Palle S, Neerati P: **Improved neuroprotective effect of resveratrol nanoparticles as evinced by abrogation of rotenone-induced behavioral deficits and oxidative and**



- mitochondrial dysfunctions in rat model of Parkinson's disease.** *Naunyn Schmiedebergs Arch Pharmacol* 2018, **391**:445-453. (Impact Factor:3.03)
19. **Palle S, Neerati P: Quercetin nanoparticles alter pharmacokinetics of bromocriptine, reflecting its enhanced inhibitory action on liver and intestinal CYP 3A enzymes in rats.** *Xenobiotica* 2018, **48**:1028-1036. (Impact Factor:1.98)
 20. **Sirisha K, Achaiah G, Prasad N, Bhasker S, Umachander L, Malla Reddy V: Multidrug Resistance Reversal Activity of Some New Dihydropyridines Studied by IN SITU Single-Pass Intestinal Perfusion (SPIP) Method in Rat.** *Pharmaceutical Chemistry Journal* 2018, **52**:8-14.
 21. **Athukuri BL, Neerati P: Enhanced Oral Bioavailability of Domperidone with Piperine in Male Wistar Rats: Involvement of CYP3A1 and P-gp Inhibition.** *J Pharm Pharm Sci* 2017, **20**:28-37. (Impact Factor:2.40)
 22. **Athukuri BL, Neerati P: Enhanced Oral Bioavailability of Diltiazem by the Influence of Gallic Acid and Ellagic Acid in Male Wistar Rats: Involvement of CYP3A and P-gp Inhibition.** *Phytother Res* 2017, **31**:1441-1448. (Impact Factor:5.83)
 23. **Kumar M, Prasad N: Antidiabetic Activity of Seed Extract of Holoptelea Integrifolia in Streptozotocin Induced Diabetic Rats** *International Journal of Pharmacy and Biological Sciences* 2017, **6**:161-170.
 24. **Palle S, Neerati P: Enhancement of oral bioavailability of rivastigmine with quercetin nanoparticles by inhibiting CYP3A4 and esterases.** *Pharmacol Rep* 2017, **69**:365-370. (Impact Factor:3.03).
 25. **Palle S, Neerati P: Quercetin nanoparticles attenuates scopolamine induced spatial memory deficits and pathological damages in rats.** *Bulletin of Faculty of Pharmacy, Cairo University* 2017, **55**:101-106.
 26. **Roy K, Neerati P, Cheung CHA, Kanwar RK, Sandhir R, Kanwar JR: Topical Ophthalmic Formulation of Trichostatin A and SurR9-C84A for Quick Recovery Post-alkali Burn of Corneal Haze.** *Front Pharmacol* 2017, **8**:223. (Impact Factor:5.83)
 27. **Sriramoju B, Neerati P, Kanwar RK, Kanwar JR: Corrigendum to "Brain targeted PLGA nanocarriers alleviating amyloid-B expression and preserving basal survivin in degenerating mice model.** *Biochim Biophys Acta* 2015, **1852**(11):2423-31. *Biochim Biophys Acta Mol Basis Dis* 2017, **1863**:2999. (Impact Factor: 5.187).
 28. **Bedada SK, Neerati P: Resveratrol Pretreatment Affects CYP2E1 Activity of Chlorzoxazone in Healthy Human Volunteers.** *Phytother Res* 2016, **30**:463-468. (Impact Factor:5.83)
 29. **Bedada SK, Yellu NR, Neerati P: Effect of resveratrol on the pharmacokinetics of fexofenadine in rats: Involvement of P-glycoprotein inhibition.** *Pharmacol Rep* 2016, **68**:338-343. (Impact Factor:3.03).
 30. **Prasad N, Bhargavi Latha A, Kumar YS, Rao YM: Development and Application of HPLC Method for Clinical Pharmacokinetic Study of Domperidone.** *International Journal of Pharmaceutical Sciences and Nanotechnology* 2016, **9**.



31. Athukuri BL, Neerati P: **Enhanced oral bioavailability of metoprolol with gallic acid and ellagic acid in male Wistar rats: involvement of CYP2D6 inhibition.** *Drug Metab Pers Ther* 2016, **31**:229-234. (Impact Factor:1.7)
32. Bedada SK, Neerati P: **Effect of resveratrol on the pharmacokinetics of carbamazepine in healthy human volunteers.** *Phytotherapy Research* 2015, **29**:701-706. (Impact Factor:5.83)
33. Edwards SL, Poongavanam V, Kanwar JR, Roy K, Hillman KM, Prasad N, Leth-Larsen R, Petersen M, Marušič M, Plavec J: **Targeting VEGF with LNA-stabilized G-rich oligonucleotide for efficient breast cancer inhibition.** *Chemical Communications* 2015, **51**:9499-9502. (Impact Factor:6.22)
34. Kanwar JR, Mahidhara G, Roy K, Sasidharan S, Krishnakumar S, Prasad N, Sehgal R, Kanwar RK: **Fe-bLf nanof ormulation targets survivin to kill colon cancer stem cells and maintains absorption of iron, calcium and zinc.** *Nanomedicine* 2015, **10**:35-55. (Impact Factor:5.33)
35. Neerati P: **Detection of antidiabetic activity by crude paratoid gland secretions from common Indian toad (Bufo melanostictus).** *Journal of natural science, biology, and medicine* 2015, **6**:429. (Impact Factor:0.672)
36. Neerati P, Bedada SK: **Effect of diosmin on the intestinal absorption and pharmacokinetics of fexofenadine in rats.** *Pharmacological Reports* 2015, **67**:339-344. (Impact Factor:3.03).
37. Sriramoju B, Neerati P, Kanwar RK, Kanwar JR: **Brain targeted PLGA nanocarriers alleviating amyloid-B expression and preserving basal survivin in degenerating mice model.** *Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease* 2015, **1852**:2423-2431. (Impact Factor:5.18).
38. Bedada SK, Yakkanti SA, Neerati P: **Resveratrol enhances the bioavailability of fexofenadine in healthy human male volunteers: involvement of P-glycoprotein inhibition.** *J Bioequiv and biovailab* 2014, **6**:158-163.
39. Neerati P: **Influence of Piperine on pioglitazone metabolism and Pk/Pd: Diabetes mellitus.** *Journal of Diabetes & Metabolism* 2014, **5**:1-7.
40. Neerati P, Devde R, Gangi AK: **Evaluation of the effect of curcumin capsules on glyburide therapy in patients with type-2 diabetes mellitus.** *Phytotherapy Research* 2014, **28**:1796-1800. (Impact Factor:5.83)
41. Neerati R, Meesala A, Talari S, Neerati P, Yanamala V: **Effect of Physostigmine on Cardiotonic Activity of Parotoid Gland Secretion of BUFO MELANOSTICTUS (SCHNEIDER) on Isolated Heart of Frog.** *World Journal of Pharmaceutical Research* 2014, **3**:657-668.
42. Raju Neerati AM, Samatha Talari, Prasad Neerati, Yanamala V: **Cardiotonic activity of Parotoid gland secretion of common Indian Toad Bufo melanostictus on isolated heart of frog.** *ISOR J of Pharmacy* 2014, **4**:61-67.
43. D.V.R.N. BhikshapathiN. Prasad VK: **A study on the effects of Borrelidin on cardiovascular and intestinals smooth muscles.** *Der Pharmacia Lettre* 2013, **5**:83-87. (Impact Factor:0.155)



44. Gurudevan S, K Kanwar R, N Veedu R, Sasidharan S, L Kennedy R, Walder K, Prasad N, R Kanwar J: **Targeted multimodal liposomes for nano-delivery and imaging: an avenger for drug resistance and cancer.** *Current gene therapy* 2013, **13**:322-334. (Impact Factor:4.35)
45. Neerati P, Sudhakar YA, Kanwar JR: **Curcumin regulates colon cancer by inhibiting P-glycoprotein in in-situ cancerous colon perfusion rat model.** *Journal of cancer science & therapy* 2013, **5**:313.
46. Neerati P, Chenna K: **Effects of ritonavir on the pharmacokinetics and pharmacodynamics of pioglitazone in normal and diabetic rats.** *Journal of Pharmacy Research* 2012, **5**:958-962.
47. Neerati P, Mohammad R, Bangaru R, Devde R, Kanwar J: **The effects of verapamil, curcumin, and capsaicin pretreatments on the BBB uptake clearance of digoxin in rats.** *J Pharm Res* 2012, **5**:2126-2133.
48. Neerati P, Ravi Karan M, Kanwar J: **Influence of curcumin on pioglitazone metabolism and Pk/Pd: diabetes mellitus.** *J Diabetes Metab S* 2012, **6**:2.
49. Neeratia P, Bangaru R, Kanwarb JR: **Pharmacoresistance of antiepileptic drugs and the role of p-glycoprotein at BBB.** *Journal of Pharmacy Research* 2012, **5**:2315-2320.
50. Prasad N, Bhasker S: **Characterization of intestinal transport of Vincristine in rats applying in situ single pass intestinal perfusion.** *Pharmacologia* 2012, **3**:617-621.
51. N. Prasad BR, B. Satish: **Influence of Diabetes mellitus on P-gp function in rat intestine.** *Pharmacologia* 2011, **2**:293-298.
52. Neerati P, Barla R, Bedada S: **Influence of diabetes mellitus on P-glycoprotein function in rat intestine.** *Pharmacologia* 2011, **2**:293-298.
53. Neerati P, Gade J: **Influence of atorvastatin on the pharmacokinetics and pharmacodynamics of glyburide in normal and diabetic rats.** *European Journal of Pharmaceutical Sciences* 2011, **42**:285-289. (Impact Factor:4.389)
54. Neerati P, Ganji D, Bedada SK: **Study on in situ and in vivo absorption kinetics of phenytoin by modulating P-glycoprotein with verapamil in rats.** *European journal of pharmaceutical sciences* 2011, **44**:27-31. (Impact Factor:4.389)
55. Neerati P, Muralikrishna G: **Influence of Itraconazole a P-Glycoprotein Inhibitor on the Pharmacodynamics of Glibenclamide in Rats.** *Journal of Advanced Pharmaceutical Sciences* 2011, **1**.
56. Prasad N, Krishna DR: **Developing Chick Embryo Diabetes Model for Screening of Anti Diabetic Drugs.** *International Journal of Pharmacology and Biological Sciences* 2010, **4**:39.
57. Venkatesham A, Prasad N, Krishna DR, Reddy YN: **Dipeptidyl peptidase-IV (DPP-IV) inhibitory activity of parotid exudate of Bufo melanostictus.** *Pharmacognosy Research* 2009, **1**.
58. G. Rajyalakshmi TR, Prasad N: **Antioxidant activity of red kino tree using Frog heart model.** *Pharmacologyonline* 2008, **3**:26-31. (Impact Factor:0.22)
59. N. Prasad ARNR, A.Venkatesham, D R Krishna, Prabhakara. MC: **Antioxidant Activity of Animal Bile using Frog Heart as a Model.** *Pharmacologyonline* 2008, **2**:390-396. (Impact Factor:0.22)



60. N. Prasad AV, V.Uday kiran, D.R. Krishna, Prabhakara MC: **Local anesthetic activity of some animal bile secretions.** *Pharmacologyonline* 2008, **2**:857-862. (Impact Factor:0.22)
61. N. Prasad AV, A. RamaNasimha Reddy, D.R Krishna, Prabhakara MC: **Evaluation of Antioxident Activity of Different Animals Bile secretions.** *International Journal of Pharmacological and Biological Sciences* 2008, **2**:131-133.
62. N. Prasad DRK, Prabhakara MC: **Intranasal administration of rifampicin in pre and post MDT infectivity among leprosy patients.** *International Journal of Pharmacological and Biological Sciences* 2008, **4**:61-70.
63. N.Prasad ARNR, A.Venkatesham, S.Pranavi, D.R.Krishna, Prabhakara. MC: **Effect of Animal Bile on the Actions of Acetylcholine using isolated Frogs Rectus Abdominus Muscle.** *Indian Journal of Comparative Animal Physiology* 2008, **26**:1-4.
64. Neerati P, Chinnappa P: **Drugs of animal origin used in Indian system of medicine.** *Pharmacologia* 2008, **3**:37-37.
65. P.M.Manjunath YV, N.Prasad, D.R.Krishna, M.C.Prabhakara, V.Lakshmipathi: **Pharmacological effects of Organic solvents (methanol and acetone) extracts of parotid exudates of Common Indian toad (Bufo malinostictus) on isolated heart of frog.** *Indian Journal of Comparative Animal Physiology* 2008, **2**:73-76.
66. Prasad N, Reddy A, Venkatesham A, Krishna D, Prabhakara M: **Antioxidant activity of animal bile using frog heart as a model.** *Pharmacol Online* 2008, **2**:390-396. (Impact Factor:0.22)
67. Pullingila Shankaraiah AV, Neerati Prasad, Devarakonda .R. Krishna, Reddy yN: **Does aspirin pretreatment prevent diabetes in rats.** *Pharmacologyonline* 2008, **3**:596-604. (Impact Factor:0.22)
68. Rajyalakshmi G, Radhika T, Prasad N: **Antioxidant activity of red Kino tree using frog heart model.** *Pharmacology online* 2008, **3**:26-31. (Impact Factor:0.22)
69. Nagulu M NP, Y Narasimhar Reddy, Y Venkaiha, V Udaykiran, D R. Krishna, Prabhakar. MC: **Frog rectum as new experimental model in pharmacology.** *Indian Journal of Comparative Animal Physiology* 2006, **2**:66-69.

RESEARCH PROJECTS COMPLETED

SL NO	Title of Project	Funding Agency	Amount INR	Date of sanction and Duration
1	Absorption kinetic study of P-gp drug substrates by perfusion technique using rat model	University Grants Commission, India. (Major Research Project)	7 Lakhs	F.36-130/2009(SR) 01.04.2009-31.03.2012 (3-years) Completed
2	Multidrug transporter P-gp role in the brain diseases and pharmacoresistance by	All India Council for Technical Education, India. (Research	14.2 Lakhs	F.8023/BOR?RID/RPS-107/2009-10. 31.03.2010-30.04.12



	using in situ brain perfusion technique in rats	Promotion Scheme)		(2-years) Completed
3	In vitro hiv type 1 reverse transcriptase inhibitory activities of some active compounds from phyllanthus emblica fruits	DBT (Department of biotechnology) Inter institutional project	47.5 Lacks	BT/PR8289/MED/29/7 17/2013. 31. 03.2014 to 30.02.2017 (active;3- years) Completed

OTHER INFORMATION

ORCID	: https://orcid.org/ 0000-0002-7145-1699
RESEARCHER ID	: Web of Science Researcher ID - <u>E-7939-2019</u>
h-INDEX	: 16
i-10 Index	: 23
Web of Science INDEX	: 12
Cumilative IF	: 107.396

Besides the publications in reputed journals I am serving as an active reviewer of research articles from the reputed journals like **British Journal of Pharmacology, Scientific Reports, Phytotherapy Research, Pharmacological reports, Natural products research, Canadian Journal of Pharmacology and Physiology, Toxicon, European Journal of Pharmaceutical Sciences, Frontier's in Pharmacology, Xenobiotica and Drug Delivery**. My research is strengthened with international collaboration with the Nanomedicine-Laboratory of Immunology and Molecular Biomedical Research in Nanomedicine (LIMBR- Deakin University) Deakin University, Australia.